SCHEDULE: Janus Henderson Discloses 7.8% Stake in Ascendis Pharma

Janus Henderson Group plc has filed an Amendment No. 8 to Schedule 13G, reporting a 7.8% beneficial ownership stake in Ascendis Pharma A/S.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, reported beneficial ownership of 4,323,059 American Depositary Shares of Ascendis Pharma A/S.
• This ownership represents 7.8% of the class of securities.
• The filing is an Amendment No. 8 to Schedule 13G, indicating an update to a previously reported stake.
• Janus Henderson Group plc holds shared voting power and shared dispositive power over all 4,323,059 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ascendis Pharma A/S.

Sentiment

Score: 5

Explanation: This is a factual beneficial ownership report (Schedule 13G) and does not contain information that inherently conveys positive or negative sentiment regarding the issuer's operational performance or future prospects. It simply reports an institutional investor's stake.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group plc, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Ascendis Pharma A/S.

Industry Context

This filing is a standard disclosure of institutional ownership, common in the financial industry, and does not provide specific insights into broader industry trends for the biotechnology or pharmaceutical sector beyond indicating an investment firm's position in a company within that sector.

Stakeholder Impact

• Shareholders of Ascendis Pharma A/S are informed of a significant institutional investor's continued or updated stake, which can influence market perception and trading activity.

Key Dates

Keywords

Ascendis Pharma, Janus Henderson, Schedule 13G, Beneficial Ownership, Institutional Investor, American Depositary Shares, Biotechnology, Pharmaceuticals